Segments - Medical Marijuana Market by Applications (Arthritis, Cancer, Chronic Pain, and Migraine) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global medical marijuana market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing awareness regarding various medical applications such as reducing eye pressure, pain management, and appetite improvement.
Medical marijuana refers to the cannabis sativa or cannabis indica plant, which is widely applied for medical purposes to treat or relieve symptoms of illnesses and ailments. Until the early 1900s, the marijuana plant was utilized medically for centuries all over the world. However, manufacturers are working on developing new products to be used by a larger audience worldwide. The legalization of medical marijuana in developed nations is predicted to increase demand for the marijuana-based drug as an alternative to traditional therapy.
As per the New York's "New Medical Marijuana Law", a patient who has identification card enrolled with the New York State Department of Health along with healthcare practitioner approval is qualified to use medical marijuana for pain management. Furthermore, multiple dispensary chains are involved in the transportation of medical marijuana between states in the US in order to ensure continuous availability in the marketplace, resulting in an adequate supply of medical marijuana across geographies. The French Agency for the Safety of Medicines and Health Products declared in October 2020 that a small medical marijuana trial would be conducted in 2021.
The COVID-19 pandemic has had a significant impact on the market as there is no clear evidence of the impact of marijuana on coronavirus infected patients. The ability of marijuana to diminish the virus's ability to cause inflammation was investigated at Augusta University in Georgia, although the notion has yet to be proven in human sources.
The report on the global medical marijuana market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Medical Marijuana Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Applications (Arthritis, Cancer, Chronic Pain, and Migraine) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
GreenGro Technologies, Inc.; Cara Therapeutics Inc.; Growblox Sciences, Inc.; Cannabis Sativa, Inc.; Lexaria Corp.; International Consolidated Companies Inc.; CannaGrow Holdings, Inc.; United Cannabis Corp.; and GW Pharmaceuticals plc. |
On the basis of applications, the global medical marijuana market is segregated as arthritis, cancer, chronic pain, and migraine. The chronic pain segment is projected to expand at a considerable CAGR during the forecast period. The growth of the segment is attributed to the ongoing numerous clinical trials with marijuana to treat neuropathic and chronic pain.
According to the National Health Service of the United Kingdom in 2019, around 28 million individuals in the United Kingdom suffered from chronic pain, and with 10-14% of them suffering from moderate-to-severe unbearable pain. With the rising prevalence of chronic pain, numerous researchers are examining the various treatment options. Additionally, many studies have revealed that medicinal marijuana is an effective treatment for chronic pain and is far safer than many other treatments. It is a cost-effective and natural solution, which has less side effects.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the marijuana legalization especially in the US. Furthermore, many marijuana initiatives have been started in the US, and most states have begun to approach medicinal marijuana from the point of good public health. As per the National Conference of State Legislatures (NCSL) 2021, 36 states have completely adopted the broadly available medical marijuana programs including the District of Guam, Puerto Rico, Columbia, and the US Virgin Islands. The National Institutes of Health (NIH) has given a USD 3.5 million grant to the University of California, Los Angeles (UCLA) in November 2019 in order to examine the effectiveness of marijuana in pain management. Such initiatives undertaken by governments are fueling the market growth of the region.
Segments Covered in the Report
The global medical marijuana market has been segmented on the basis of
Applications
Regions
Key Players
Some of the major companies competing in the market are GreenGro Technologies, Inc.; Cara Therapeutics Inc.; Growblox Sciences, Inc.; Cannabis Sativa, Inc.; Lexaria Corp.; International Consolidated Companies Inc.; CannaGrow Holdings, Inc.; United Cannabis Corp.; and GW Pharmaceuticals plc. Some of these main players have adopted several business strategies including partnerships, products launching, mergers, and capacity expansion to expand their market coverage globally.
Dharma Pharmaceuticals, a Virginia-based company, has started its Virginia's first medical marijuana dispensary in October 2020. In another event, Aurora Cannabis has acquired Hempco Food and Fiber Inc.; that provides cost effective hemp raw materials for extraction, in August 2019. After this acquisition, the company aimed to strengthen its position in the hemp food and hemp-derived cannabidiol (CBD) industries in the US. Moreover, in January 2019, Aphria completed the acquisition of CC Pharma, a German- based company that distributes a variety of medicinal products including medical cannabis many countries of Europe especially in Germany.
Chronic pain is a major segment due to numerous clinical trials demonstrating the effectiveness and safety of medical marijuana for pain management, making it a cost-effective and natural alternative with fewer side effects.
Opportunities include increased investment in marijuana testing laboratories, rising adoption among the geriatric population, and ongoing research and development for new medical marijuana products.
Major companies in the market include GreenGro Technologies, Inc.; Cara Therapeutics Inc.; Growblox Sciences, Inc.; Cannabis Sativa, Inc.; Lexaria Corp.; International Consolidated Companies Inc.; CannaGrow Holdings, Inc.; United Cannabis Corp.; and GW Pharmaceuticals plc.
The COVID-19 pandemic had a significant impact on the market, with ongoing research into marijuana's potential to reduce inflammation caused by the virus, though its effectiveness has not yet been proven in humans.
The market is segmented by applications such as arthritis, cancer, chronic pain, and migraine, with chronic pain being a significant and fast-growing segment.
Key challenges include high costs of testing tools, lack of skilled technicians, and stringent government regulations to ensure quality production and maximize cultivation processes.
North America, especially the United States, is anticipated to hold a key market share due to widespread legalization and government initiatives supporting medical marijuana programs.
Legalization of medical marijuana in developed nations has increased demand for marijuana-based drugs as alternatives to traditional therapies, boosting market growth and encouraging product development.
Medical marijuana is used for various applications such as reducing eye pressure, pain management, and improving appetite. It is also used to treat conditions like arthritis, cancer, chronic pain, and migraine.
The global medical marijuana market is estimated to expand at a substantial CAGR during the forecast period of 2021 to 2028, driven by increasing awareness of its medical applications.